Chemomab Therapeutics (CMMB) Competitors $1.16 0.00 (-0.32%) Closing price 07/11/2025 03:57 PM EasternExtended Trading$1.18 +0.03 (+2.40%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB vs. ADAG, ONCY, CLYM, ELUT, ENTX, TCRX, EXOZ, CABA, JMAC, and IGMSShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Adagene (ADAG), Oncolytics Biotech (ONCY), Climb Bio (CLYM), Elutia (ELUT), Entera Bio (ENTX), TScan Therapeutics (TCRX), eXoZymes (EXOZ), Cabaletta Bio (CABA), Maxpro Capital Acquisition (JMAC), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Its Competitors Adagene Oncolytics Biotech Climb Bio Elutia Entera Bio TScan Therapeutics eXoZymes Cabaletta Bio Maxpro Capital Acquisition IGM Biosciences Adagene (NASDAQ:ADAG) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Do analysts prefer ADAG or CMMB? Adagene presently has a consensus target price of $8.00, indicating a potential upside of 318.85%. Chemomab Therapeutics has a consensus target price of $8.50, indicating a potential upside of 635.10%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ADAG or CMMB? Adagene has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Which has stronger valuation & earnings, ADAG or CMMB? Chemomab Therapeutics has lower revenue, but higher earnings than Adagene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$100K899.80-$33.42MN/AN/AChemomab TherapeuticsN/AN/A-$13.94M-$0.76-1.52 Do insiders & institutionals have more ownership in ADAG or CMMB? 9.5% of Adagene shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to ADAG or CMMB? In the previous week, Adagene had 3 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 4 mentions for Adagene and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.89 beat Adagene's score of 0.79 indicating that Chemomab Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Adagene Positive Chemomab Therapeutics Very Positive Is ADAG or CMMB more profitable? Adagene's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Chemomab Therapeutics N/A -106.70%-82.18% SummaryAdagene and Chemomab Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.80M$2.94B$5.56B$9.11BDividend YieldN/A2.45%5.07%4.01%P/E Ratio-1.528.8121.2120.54Price / SalesN/A292.00432.0899.78Price / CashN/A42.1137.1257.67Price / Book1.617.638.045.49Net Income-$13.94M-$55.05M$3.19B$250.45M7 Day Performance-2.01%8.43%3.63%4.79%1 Month Performance-5.22%5.42%4.06%7.68%1 Year Performance4.26%2.03%30.02%16.43% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics2.7939 of 5 stars$1.16-0.3%$8.50+635.1%+1.4%$21.80MN/A-1.5220Positive NewsGap UpADAGAdagene2.5946 of 5 stars$1.95+5.4%$8.00+310.3%-29.5%$87.15M$100K0.00260Gap UpONCYOncolytics Biotech1.8324 of 5 stars$1.01+9.8%$4.33+329.0%+15.7%$86.73MN/A-3.4830News CoverageGap DownHigh Trading VolumeCLYMClimb Bio3.5185 of 5 stars$1.26-1.6%$9.00+614.3%N/A$86.50MN/A-0.539News CoveragePositive NewsELUTElutia3.4444 of 5 stars$2.08-0.5%$8.00+284.6%-47.8%$85.93M$24.38M-1.08180ENTXEntera Bio2.7213 of 5 stars$1.83-3.2%$10.00+446.4%-9.4%$85.91M$180K-7.0420TCRXTScan Therapeutics3.6113 of 5 stars$1.45-4.0%$7.80+437.9%-73.5%$85.45M$2.82M-1.33100News CoveragePositive NewsAnalyst UpgradeEXOZeXoZymesN/A$10.18+2.7%N/AN/A$82.93M$70K0.0029Positive NewsGap DownCABACabaletta Bio2.6144 of 5 stars$1.49-8.6%$14.43+868.4%-78.8%$82.71MN/A-0.5950News CoverageJMACMaxpro Capital AcquisitionN/A$6.14-6.4%N/A+2,720.4%$82.45MN/A0.002,021News CoverageIGMSIGM Biosciences4.6217 of 5 stars$1.35-0.7%$5.50+307.4%-85.4%$81.29M$2.68M-0.41190High Trading Volume Related Companies and Tools Related Companies ADAG Competitors ONCY Competitors CLYM Competitors ELUT Competitors ENTX Competitors TCRX Competitors EXOZ Competitors CABA Competitors JMAC Competitors IGMS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMMB) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
